The heart is the essence and engine of our lives, the very source of our vitality and being. Yet there are approximately 22 million people around the world forced to endure a reduced quality of life – those suffering from chronic heart failures. It was with these people in mind that we developed a completely new treatment option: MCP therapy.

The following pages provide detailed information:

• on our company
• for physicians and cardiologists
• for patients and families

Cardiola’s MCP is the only non-invasive medical device currently available to enable home treatment of chronic heart failure as a parallel supplement to drug therapy.

 

Clinical study demonstrates that Cardiola’s m.pulse® system
“immediately improves cardiac output under acute non-invasive
Muscular CounterPulsation (MCP) treatment in patients with patients
with stable CHF” (chronic heart failure)

 

Find out more

 

Cardiola collaborates with leading German cardiac center
in study of its m.pulse® system

Find out more

 

Cardiola raises $4 million from existing and new investors

Find out more

 

Cardiola penetrates European market with its Muscular
CounterPulsation (MCP)-based m.pulse® system

Find out more

 

Cardiola is on the cover of  the “KMU Spezial”, an enclosure of recently
published “Zürcher Wirtschaftsmagazin”, which is published by the

Zürcher Kantonalbank.

Here you can download the PDF.